SEARCH FOR NEW MICRORNA MARKERS FOR DIFFERENTIAL DIAGNOSIS OF DIFFERENT GRADE CEREBRAL GLIOMAS

Author: Stupak E.V.¹, Titov S.E.², Veryaskina Yu.A.³, Akhmerova L.G.⁴, Stupak V.V.⁵, Rabinovich S.S.⁶, Dolzhenko D.A.⁷, Zhimulev I.F.⁸

Author Affiliations

Abstract

Purpose of the study – searching of new microRNA markers for differential diagnostics of different grade cerebral gliomas. Material and methods. Surgical material is tumor and externally unchanged brain tissue that was obtained from 41 patients with gliomas of different grade anaplasia. In 6 patients with cerebral glioma, a high-throughput Nanostring platform was used to determine the level of expression of 800 microRNAs. 37 patients with a similar pathology were subjected to real-time PCR, microRNA-128, 143, 144, 182, 183, 199b, 204, 7, 99a. Results and discussion: It has been established with the NanoString technology that the level of expression of miRNA 199b was significantly higher in gliomas of grade III and IV than in gliomas of grade II. In contrast, the expression level of miRNA-144 and miRNA-182 was reduced. There was also a significant 10-fold increase in the level of expression of microRNA-7 in tumors of grade IV in comparison with grade II. These differences in the expression of four microRNAs in these types of gliomas can be additional markers that distinguish rapidly growing malignant gliomas (grade III, IV) from slowly growing tumors (grade II) and timely assign an adequate comprehensive treatment.

Key words

cerebral glioma, microRNA, different grade gliomas, microRNA expression, NanoString technology, PCR

References

Andorfer C.A., Necela B.M., Thompson E.A., Perez E.A. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med. 2011. 17. (6). 313–319.

Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., Barbisin M., Xu N.L., Mahuvakar V.R., Andersen M.R., Lao K.Q., Livak K.J., Guegler K.J. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005. 20. (33). e179.

Ciafre S.A., Galard S.,Mangiola A., Ferracin M., Liu C.G., Sabatino G., Negrini M., Maira G., Croce C.M., Farace M.G. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 2005. 334. 1351–1358.

Conaco C., Otto S., Han J.J., Mandel G. Reciprocal actions of REST and a microRNA promote neuronal identity. Proc. Natl. Acad. Sci. USA. 2006. 103. (7). 2422–2427.

Conti A., Aguennouz M., La Torre D., Tomasello C., Cardali S., Angileri F.F., Maio F., Cama A., Germanò A., Vita G., Tomasello F. miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol. 2009. 93. (3). 325–332.

Cristóbal I., Caramés C., Rincón R., Manso R., Madoz-Gúrpide J., Torrejón B., González-Alonso P., Rojo F., García-Foncillas J. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. Oncotarget. 2017. 8. 40169–40180.

Feng Y.A., Liu T., Wu Y. MicroRNA 182 inhibits the proliferation and migration of glioma cells through the induction of neuritin expression. Oncol. Lett. 2015. 10. (2).1197–1203.

Fu T.G., Wang L., Li W., Li J.Z., Li J. miR-143 inhibits oncogenic traits by degrading NUAK2 in glioblastoma. Int. J. Mol. Med. 2016. 37. (6). 1627–1635.

Godlewski J., Nowicki M.O., Bronisz A., Williams S., Otsuki A., Nuovo G., Raychaudhury A., Newton H.B., Chiocca E.A., Lawler S. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008. 68. 9125–9130.

Jiang L., Mao P., Song L., Wu J., Huang J., Lin C., Yuan J., Qu L., Cheng S.Y., Li J. miR-182 as a prognostic marker for glioma progression and patient survival. Am. J. Pathol. 2010. 177. (1). 29–38.

Krutovskikh V.A., Herceg Z. Oncogenic microRNAs (OnkomiRs) as a new class of cancer biomarkers. Bioessays. 2010. 32. (10). 894–904.

Kulkarni M.M. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr. Protoc. Mol. Biol. 2011. 25. 25B.10.

Law M., Young R.J., Babb J.S., Peccerelli N., Chheang S., Gruber M.L., Miller D.C., Golfinos J.G., Zagzag D., Johnson G. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008. 247. 490–498.

Liu Z., Liu J., Segura M.F., Shao C., Lee P., Gong Y., Hernando E., Wei J.J. MiR-182 overexpression in tumorigenesis of high-grade serous ovarian carcinoma. J. Pathol. 2012. 228. (2). 204–215.

Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007. 114. (2). 97–109.

Mittler M.A., Walters B.C., Stopa E.G. Observer reliability in histological grading of astrocytoma stereotactic biopsies. J. Neurosurg. 1996. 85. (6). 1091–1094.

Olyushin V.E., Filatov M.V., Ulitin A.Yu., Bazhanov S.P. Specific antitumor immunotherapy based on dendritic cells in the complex treatment of patients with malignant cerebral gliomas. Saint-Petersburg: Znak, 2012. 212 p. [In Russian].

Qu Y., Li W.C., Hellem M.R., Rostad K., Popa M., McCormack E., Oyan A.M., Kalland K.H., Ke X.S. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-suciency of growth signals via repressing SNAI2 in prostate cells. Int. J. Cancer. 2013. 133. (3). 544–555.

Sasahira T., Kurihara M., Bhawal U.K., Ueda N., Shimomoto T., Yamamoto K., Kirita T., Kuniyasu H. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br. J. Cancer. 2012. 107. (4). 700–706.

Segura M.F., Hanniford D., Menendez S., Reavie L., Zou X., Alvarez-Diaz S., Zakrzewski J., Blochin E., Rose A., Bogunovic D., Polsky D., Wei J., Lee P., Belitskaya-Levy I., Bhardwaj N., Osman I., Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. USA. 2009. 106. (6). 1814–1819.

Shi L., Cheng Z., Zhang J., Li R., Zhao P., Fu Z., You Y. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008. 1236. 185–193.

Silber J., Lim D.A., Petritsch C., Persson A.I., Maunakea A.K., Yu M., Vandenberg S.R., Ginzinger D.G., James C.D., Costello J.F., Bergers G., Weiss W.A., Alvarez-Buylla A., Hodgson J.G. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008. 6. 14.

Stupak E.V., Veriaskina Yu.A., Titov S.E., Akhmerova L.G., Stupak V.V., Mishinov S.V., Koporushko N.A., Petrova Yu.V., Pustakhanov V.V., Ivanov M.K., Zhimulyov I.F., Kolesnikov N.N. The value of mcRNA profile in the diagnostics of brain malignant gliomas. Rossiyskiy neyrokhirurgicheskiy zhurnal = Russian neurosurgical journal. 2016. 8. (2). 54–58. [In Russian].

Stupak E.V., Veryaskina Yu. A., Titov S.E., Achmerova L.G., Stupak V.V., Dolzhenko D.A., Rabinovich S.S., Zhimulev I.F., Kolesnikov N.N. Studying the MicroRNA role as a survival predictor and revealing its part in malignancy level determination in patients with supratentorialgliomas of brain. AIP Conf. Proc. 2017. 1882. 020073.

Visani M., de Biase D., Marucci G., Taccioli C., Baruzzi A. Pession Definition of miRNAs expression profile in glioblastoma samples: the relevance of non-neoplastic brain reference. PLoS One. 2013. 8. (1). e55314.

Wang L., Shi Z.M., Jiang C.F., Liu X., Chen Q.D., Qian X., Li D.M., Ge X., Wang X.F., Liu L.Z., You Y.P., Liu N., Jiang B.H. MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget. 2014. 5. 5416–5427.

Xu X., Lu Z., Qiang W., Vidimar V., Kong B., Kim J.J., Wei J.J. Inactivation of AKT induces cellular senescence in uterine leiomyoma. Endocrinology. 2014. 155. (4). 1510–1519.

Ye Z., Zhang Z., Wu L., Liu C., Chen Q., Liu J., Wang X., Zhuang Z., Li W., Xu S., Hang C. Upregulation of miR-183 expression and its clinical significance in human brain glioma. Neurol. Sci. 2016. 37. (8). 1341–1347.

Zhang Y., Chao Т., Li R., Liu W., Chen Y., Yan X., Gong Y., Yin B., Liu W., Qiang B., Zhao J., Yuan J., Peng X. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J. Mol. Med. (Berl). 2009. 87. (1). 43–51.

Zozulya Yu.A., Vasilieva I.G., Glavatsky A.Ya. Gliomas of the brain. Kiev: EksOb, 2007. 636 p. [In Russian].

About Authors (Correspondence):

Stupak E.V. – junior researcher, department of neurosurgery,e-mail: EStupak@niito.ru

Full Text

snmzh_6-2018_stupak_85-93.pdf

Received: 18/12/2018

Accepted: 18/12/2018